Actively Recruiting
177Lu-TATE-RGD in Patients With SSTR2 and Integrin αVβ3 Positive Tumors
Led by Peking Union Medical College Hospital · Updated on 2024-10-15
10
Participants Needed
1
Research Sites
24 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers has conducted extensive research on the treatment of neuroendocrine tumors with 177Lu-EB-TATE and the treatment of FAP-expressing tumors with 177Lu-EB-FAPI, and some researches have revealed 68Ga-TATE-RGD in imaging studies of neuroendocrine tumors to find that the dual-targeted tracer showed an increasing TBR, suggesting the tracer kinetic advantage of TATE-RGD; compared to the single-target tracer DOTATATE, the dual-target TATE-RGD probe has a clear advantage in detecting liver metastases of NETs, and it can be explored for potential therapeutic uses of TATE-RGD in future studies and used for related companion diagnostics in targeted radioisotope therapy (RLT).
CONDITIONS
Official Title
177Lu-TATE-RGD in Patients With SSTR2 and Integrin αVβ3 Positive Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with a clear pathological diagnosis and clinical conventional treatment that is ineffective or progressing
- Tumor lesions with high SSTR2 and RGD uptake confirmed on 68Ga-TATE-RGD PET/CT within one week before injection
- Signed written consent to participate in the study
You will not qualify if you...
- Serum creatinine level greater than 150 cmol per liter
- Hemoglobin level less than 10.0 g/dl
- White-cell count less than 4.0 109/L
- Platelet count less than 100 109/L
- Total bilirubin level more than 3 times the upper limit of normal
- Serum albumin level more than 3.0 g per deciliter
- Cardiac insufficiency including carcinoid heart valve disease
- Severe allergy or hypersensitivity to radiographic contrast material
- Claustrophobia
- Any medical condition that may significantly interfere with study compliance according to investigator opinion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese Academy of Medical Science & Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730
Actively Recruiting
Research Team
Z
Zhaohui Zhu, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here